Idiopathic Pulmonary Fibrosis Treatment Market, Global Outlook and Forecast 2022-2028

April 2022 | 62 pages | ID: I1EA125B1E11EN
Market Monitor Global

Abstracts

Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff.

This report contains market size and forecasts of Idiopathic Pulmonary Fibrosis Treatment in Global, including the following market information:

Global Idiopathic Pulmonary Fibrosis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Idiopathic Pulmonary Fibrosis Treatment market was valued at 1950.8 million in 2021 and is projected to reach US$ 3110.1 million by 2028, at a CAGR of 6.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Drug Class Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Idiopathic Pulmonary Fibrosis Treatment include Biogen, Boehringer Ingelheim GMBH, Bristol-Myers Squibb Company, Cipla, Hoffmann-La Roche AG, Fibrogen, Inc., Galapagos NV, Medicinova, Inc. and Merck & Co., Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Idiopathic Pulmonary Fibrosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Idiopathic Pulmonary Fibrosis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Idiopathic Pulmonary Fibrosis Treatment Market Segment Percentages, by Type, 2021 (%)

• Drug Class
• Oxygen Therapy
• Lung Transplant
• Others

Global Idiopathic Pulmonary Fibrosis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Idiopathic Pulmonary Fibrosis Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic

Global Idiopathic Pulmonary Fibrosis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Idiopathic Pulmonary Fibrosis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Idiopathic Pulmonary Fibrosis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Idiopathic Pulmonary Fibrosis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Biogen
• Boehringer Ingelheim GMBH
• Bristol-Myers Squibb Company
• Cipla
• Hoffmann-La Roche AG
• Fibrogen, Inc.
• Galapagos NV
• Medicinova, Inc.
• Merck & Co., Inc.
• Novartis AG
• Prometic Life Sciences Inc.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Idiopathic Pulmonary Fibrosis Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Idiopathic Pulmonary Fibrosis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT OVERALL MARKET SIZE

2.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Size: 2021 VS 2028
2.2 Global Idiopathic Pulmonary Fibrosis Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Idiopathic Pulmonary Fibrosis Treatment Players in Global Market
3.2 Top Global Idiopathic Pulmonary Fibrosis Treatment Companies Ranked by Revenue
3.3 Global Idiopathic Pulmonary Fibrosis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Idiopathic Pulmonary Fibrosis Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Idiopathic Pulmonary Fibrosis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Idiopathic Pulmonary Fibrosis Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Idiopathic Pulmonary Fibrosis Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Idiopathic Pulmonary Fibrosis Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Idiopathic Pulmonary Fibrosis Treatment Market Size Markets, 2021 & 2028
  4.1.2 Drug Class
  4.1.3 Oxygen Therapy
  4.1.4 Lung Transplant
  4.1.5 Others
4.2 By Type - Global Idiopathic Pulmonary Fibrosis Treatment Revenue & Forecasts
  4.2.1 By Type - Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Idiopathic Pulmonary Fibrosis Treatment Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
5.2 By Application - Global Idiopathic Pulmonary Fibrosis Treatment Revenue & Forecasts
  5.2.1 By Application - Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Idiopathic Pulmonary Fibrosis Treatment Market Size, 2021 & 2028
6.2 By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue & Forecasts
  6.2.1 By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2028
  6.3.2 US Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.3.3 Canada Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.3.4 Mexico Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2028
  6.4.2 Germany Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.4.3 France Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.4.4 U.K. Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.4.5 Italy Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.4.6 Russia Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.4.8 Benelux Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2028
  6.5.2 China Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.5.3 Japan Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.5.4 South Korea Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.5.6 India Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2028
  6.6.2 Brazil Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.6.3 Argentina Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2028
  6.7.2 Turkey Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.7.3 Israel Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028
  6.7.5 UAE Idiopathic Pulmonary Fibrosis Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Biogen
  7.1.1 Biogen Corporate Summary
  7.1.2 Biogen Business Overview
  7.1.3 Biogen Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.1.4 Biogen Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.1.5 Biogen Key News
7.2 Boehringer Ingelheim GMBH
  7.2.1 Boehringer Ingelheim GMBH Corporate Summary
  7.2.2 Boehringer Ingelheim GMBH Business Overview
  7.2.3 Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.2.4 Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.2.5 Boehringer Ingelheim GMBH Key News
7.3 Bristol-Myers Squibb Company
  7.3.1 Bristol-Myers Squibb Company Corporate Summary
  7.3.2 Bristol-Myers Squibb Company Business Overview
  7.3.3 Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.3.4 Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.3.5 Bristol-Myers Squibb Company Key News
7.4 Cipla
  7.4.1 Cipla Corporate Summary
  7.4.2 Cipla Business Overview
  7.4.3 Cipla Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.4.4 Cipla Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.4.5 Cipla Key News
7.5 Hoffmann-La Roche AG
  7.5.1 Hoffmann-La Roche AG Corporate Summary
  7.5.2 Hoffmann-La Roche AG Business Overview
  7.5.3 Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.5.4 Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.5.5 Hoffmann-La Roche AG Key News
7.6 Fibrogen, Inc.
  7.6.1 Fibrogen, Inc. Corporate Summary
  7.6.2 Fibrogen, Inc. Business Overview
  7.6.3 Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.6.4 Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.6.5 Fibrogen, Inc. Key News
7.7 Galapagos NV
  7.7.1 Galapagos NV Corporate Summary
  7.7.2 Galapagos NV Business Overview
  7.7.3 Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.7.4 Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.7.5 Galapagos NV Key News
7.8 Medicinova, Inc.
  7.8.1 Medicinova, Inc. Corporate Summary
  7.8.2 Medicinova, Inc. Business Overview
  7.8.3 Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.8.4 Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.8.5 Medicinova, Inc. Key News
7.9 Merck & Co., Inc.
  7.9.1 Merck & Co., Inc. Corporate Summary
  7.9.2 Merck & Co., Inc. Business Overview
  7.9.3 Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.9.4 Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.9.5 Merck & Co., Inc. Key News
7.10 Novartis AG
  7.10.1 Novartis AG Corporate Summary
  7.10.2 Novartis AG Business Overview
  7.10.3 Novartis AG Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.10.4 Novartis AG Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.10.5 Novartis AG Key News
7.11 Prometic Life Sciences Inc.
  7.11.1 Prometic Life Sciences Inc. Corporate Summary
  7.11.2 Prometic Life Sciences Inc. Business Overview
  7.11.3 Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Major Product Offerings
  7.11.4 Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue in Global Market (2017-2022)
  7.11.5 Prometic Life Sciences Inc. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Idiopathic Pulmonary Fibrosis Treatment Market Opportunities & Trends in Global Market
Table 2. Idiopathic Pulmonary Fibrosis Treatment Market Drivers in Global Market
Table 3. Idiopathic Pulmonary Fibrosis Treatment Market Restraints in Global Market
Table 4. Key Players of Idiopathic Pulmonary Fibrosis Treatment in Global Market
Table 5. Top Idiopathic Pulmonary Fibrosis Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Idiopathic Pulmonary Fibrosis Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Idiopathic Pulmonary Fibrosis Treatment Product Type
Table 9. List of Global Tier 1 Idiopathic Pulmonary Fibrosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Idiopathic Pulmonary Fibrosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Idiopathic Pulmonary Fibrosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Idiopathic Pulmonary Fibrosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Idiopathic Pulmonary Fibrosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Idiopathic Pulmonary Fibrosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Biogen Corporate Summary
Table 31. Biogen Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 32. Biogen Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Boehringer Ingelheim GMBH Corporate Summary
Table 34. Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 35. Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Bristol-Myers Squibb Company Corporate Summary
Table 37. Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 38. Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Cipla Corporate Summary
Table 40. Cipla Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 41. Cipla Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Hoffmann-La Roche AG Corporate Summary
Table 43. Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 44. Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Fibrogen, Inc. Corporate Summary
Table 46. Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 47. Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Galapagos NV Corporate Summary
Table 49. Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 50. Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Medicinova, Inc. Corporate Summary
Table 52. Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 53. Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Merck & Co., Inc. Corporate Summary
Table 55. Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 56. Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Novartis AG Corporate Summary
Table 58. Novartis AG Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 59. Novartis AG Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Prometic Life Sciences Inc. Corporate Summary
Table 61. Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Product Offerings
Table 62. Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Idiopathic Pulmonary Fibrosis Treatment Segment by Type in 2021
Figure 2. Idiopathic Pulmonary Fibrosis Treatment Segment by Application in 2021
Figure 3. Global Idiopathic Pulmonary Fibrosis Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Idiopathic Pulmonary Fibrosis Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Idiopathic Pulmonary Fibrosis Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Treatment Revenue in 2021
Figure 8. By Type - Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 12. US Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 24. China Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Idiopathic Pulmonary Fibrosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Biogen Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Cipla Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Novartis AG Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)